FBB
HZNP

Fulton Breakefield Broenniman’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Fulton Breakefield Broenniman’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,649
Closed -$439K – 178
2020
Q3 		$439K Buy
+5,649
New +$389K 0.05% 115

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fulton Breakefield Broenniman's HZNP Position: Q4 2020 in Review

Fulton Breakefield Broenniman sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2020, closing a stake of 5,649 shares — an estimated $439K sold.

Fulton Breakefield Broenniman first reported a position in HZNP in Q3 2020 and held it in 1 quarter. The position peaked at $439K in Q3 2020. 497 funds tracked by Wall St. Rank hold HZNP as of Q4 2020.

  • Fulton Breakefield Broenniman reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2020 after selling out during the quarter.
  • Fulton Breakefield Broenniman sold 5,649 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2020, an estimated $439K.
  • Fulton Breakefield Broenniman first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 1 quarter.
  • Fulton Breakefield Broenniman's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $439K in Q3 2020.
  • 497 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2020.

Based on Fulton Breakefield Broenniman's 13F filing for Q4 2020, filed 14 Jan 2021.